Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Refo
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2
... , BEIJING, China , July 6 ... the development, assembly,marketing and sale of medical devices and homecare medical products in ... EPS for,fiscal year 2010. , , ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) , ...
... Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today ... by Taconic Artemis and Taconic Farms Inc in December 2008 ... , , , ... of the Tribunal de Grande Instance decided on Tuesday, June 29 ...
... July 6 Novavax, Inc. (Nasdaq: NVAX ... M.D., as the company,s Chief Scientific Officer who will report ... Officer of Novavax.  Previously, Dr. Glenn was Chief Scientific Officer ... international health at Johns Hopkins University,s School of Public ...
Cached Biology Technology:Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 2Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 3Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010 4Taconic's Litigation Contesting License Termination By Cellectis Is Dismissed 2Taconic's Litigation Contesting License Termination By Cellectis Is Dismissed 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:7/10/2014)... -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the ... was interviewed on July 1 st on the ... . Mr. Pereira discusses the company,s next generation smart wallet ... the Wocket™ aims to replace a traditional wallet with a ... tells Gino he has never heard of the Wocket ...
(Date:7/10/2014)... , July 3, 2014 Research and ... of the "Global Gesture Recognition & Touch-Less ... Forecasts to 2020" report to their offering ... Global Gesture Recognition & Touch-Less Sensing Market to ... for a while, but the companies were unable ...
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
... Entering a new domain . . . ... at Oak Ridge National Laboratory,s Center for Nanophase ... discoveries that could open new pathways for nanoscale ... ( http://www.nature.com/nmat/journal/vaop/ncurrent/abs/nmat2373 ) and led by Ramamoorthy ...
... physical and emotional toll on our bodies and scientists are ... we respond to stress at the cellular level in the ... stress is essential for survival. Using a rat ... his team of researchers at the Hotchkiss Brain Institute have ...
... across the country will convene on the University of Houston ... public health issues and intervention strategies. , The ... April 9 10 at the UH M.D. Anderson Library, ... inaugural conference and have high hopes that others will see ...
Cached Biology News:Story tips from the Departments of Energy's Oak Ridge National Lab -- March 2009 2Story tips from the Departments of Energy's Oak Ridge National Lab -- March 2009 3New and unexpected mechanism identified how the brain responds to stress 2Texas Obesity Research Center at UH assembles researchers to discuss obesity 2
Human Cell Line Slides...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: